Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing products for cancer patients. Its proprietary targeted anti-cancer agents are designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Its product candidate oral rigosertib, is currently in a dose-escalation and expansion Phase 1 investigator-initiated study, targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.
The company is dedictated to delivering novel solutions to cancer patients who are in need. It seeks to develop products that enhance the outcome for cancer patients by addressing the disease, its recurrence, and the burden of side-effects that are associated with the current methods of treatment.